Skip to main content
AmigoFish

How Leyden Labs is revolutionizing flu protection with its intranasal antibody spray

From Beyond Biotech - the podcast from Labiotech · · 32 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs (https://leydenlabs.com), and Clarissa Koch, the company's Chief Scientific Officer.

Leyden Labs is pioneering a revolutionary non-vaccine approach to combat respiratory viruses like influenza and coronaviruses. Recently, they published groundbreaking data in Science Translational Medicine (https://www.science.org/doi/10.1126/scitranslmed.adz1580), demonstrating that their intranasal antibody spray is safe, well-tolerated, and delivers sustained protection right at the virus's entry point: the nose. This innovation addresses the shortcomings of traditional flu vaccines, which average just 13% effectiveness against infection and provide even less for vulnerable groups like the elderly and immunocompromised.

We'll dive into the science, the company's journey since its 2020 founding, and their recent €50 million European funding boost amid U.S. biotech challenges.

01:33: Meet Koenraad Wiedhaup

03:13: Meet Clarissa Koch

04:16: Leyden Labs' origin story

06:21: Mucosal protection platform explained

08:57: Complementing existing vaccines

11:47: Science of mucosal immunity

13:24: PanFlu lead candidate overview

16:42: Key findings from recent publication

22:02: Funding and future preparedness

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast)

Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast)

To dive deeper into the topic:

- Seven biotech companies to know in the Netherlands (https://www.labiotech.eu/best-biotech/biotech-companies-the-netherlands/)

- The Netherlands’ biotech scene: The country sets its sights on becoming a global leader by 2040 (https://www.labiotech.eu/in-depth/the-netherlands-biotech-hub/)

- Influenza solution deals pile up as pandemic preparedness increases (https://www.labiotech.eu/trends-news/influenza-deals-surge/)

Back to Beyond Biotech - the podcast from Labiotech · Report a problem